<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610736</url>
  </required_header>
  <id_info>
    <org_study_id>ORP-TMZ-I- b</org_study_id>
    <nct_id>NCT04610736</nct_id>
  </id_info>
  <brief_title>TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide</brief_title>
  <official_title>TEMOkids Study: A Population Pharmacokinetic, Acceptability and Safety Study for KIMOZO, a Paediatric Oral Suspension of Temozolomide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orphelia Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinSearch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Orphelia Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-randomized, international, multi-centre, open-label, single arm study to determine the&#xD;
      pharmacokinetic (PK) parameters of a single dose of an oral suspension of temozolomide&#xD;
      (KIMOZO) in the pediatric population aged 1 year and over.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TEMOkids study is an international open-label, non-randomized, prospective, single-arm&#xD;
      phase 1 study to determine the pharmacokinetic (PK) parameters of a single dose of an oral&#xD;
      suspension of temozolomide (KIMOZO) in the pediatric population aged 1 year and over.&#xD;
&#xD;
      Patients will be subject to at least one 21 or 28-day treatment cycle involving&#xD;
      administration of an oral suspension of temozolomide (KIMOZO) for five consecutive days&#xD;
      followed by 16 or 23-days resting period, with determination of the PK parameters on the&#xD;
      first treatment day.&#xD;
&#xD;
      Five (5) additional cycles will be allowed under compassionate use regimen. The compassionate&#xD;
      use period could be extended at the discretion of the investigator and in agreement with the&#xD;
      sponsor. Safety and activity data will be collected during the compassionate follow-up&#xD;
      period.&#xD;
&#xD;
      The study will be held in multiple sites spread across Europe.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Non-randomized, international, multi-centre, open-label, single arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Population Phamacokinetic parameter: AUC24</measure>
    <time_frame>At Day 1 of treatment cycle 1 (each cycle is 21 or 28 days) with post-dose samples collected at about 0.15, 0.5, 1, 2.5, and 7 hours post dose</time_frame>
    <description>Estimated by a population analysis performed with NONMEM (7.4)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Population Phamacokinetic parameter: Cmax</measure>
    <time_frame>At Day 1 of treatment cycle 1 (each cycle is 21 or 28 days) with post-dose samples collected at about 0.15, 0.5, 1, 2.5, and 7 hours post dose</time_frame>
    <description>Estimated by a population analysis performed with NONMEM (7.4)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Population Phamacokinetic parameter: T1/2</measure>
    <time_frame>At Day 1 of treatment cycle 1 (each cycle is 21 or 28 days) with post-dose samples collected at about 0.15, 0.5, 1, 2.5, and 7 hours post dose</time_frame>
    <description>Estimated by a population analysis performed with NONMEM (7.4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability of the oral suspension of temozolomide: score</measure>
    <time_frame>At Day 1 and Day 5 of treatment cycle 1 (each cycle is 21 or 28 days)</time_frame>
    <description>Scoring with a standardized assessment tool: CAST - ClinSearch Acceptability Score Test®. This tool measures 9 observational drivers of drug acceptability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Through study completion, an average of 6 months including compassionate use period</time_frame>
    <description>Adverse events collected directly by investigators when patient is hospitalized and through patient diary completed by caregivers and medically controlled by investigators when patient is at home</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of the oral suspension of temozolomide</measure>
    <time_frame>At the end of each 21- or 28-day treatment cycle of the compassionate use period</time_frame>
    <description>Activity assessment (complete or partial response, stable disease, disease progression)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pediatric Cancer</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide 40 mg/ml, Oral suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide Oral Suspension</intervention_name>
    <description>One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>KIMOZO, Ped-TMZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients in need of temozolomide (all indications with 5-day treatment per&#xD;
             21- or 28-day cycle).&#xD;
&#xD;
          -  Male and female patients aged 1 to less than 18 years&#xD;
&#xD;
          -  Patients who have signed the informed consent or for which one, both parents or legal&#xD;
             guardian (depending on local legislation) have signed the informed consent.&#xD;
&#xD;
          -  Patients having records of coverage by a health insurance&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Adequate haematological function:&#xD;
&#xD;
               -  haemoglobin ≥ 80 g/L (transfusion support authorized)&#xD;
&#xD;
               -  neutrophil count ≥ 1.0 x 10e9 cells/L&#xD;
&#xD;
               -  platelet count ≥ 100 x 10e9 cells/L (without transfusion support)&#xD;
&#xD;
               -  in case of bone marrow involvement: neutrophils ≥ 0.5 x 10e9 cells/L and&#xD;
                  platelets ≥75 x 10e9 cells/L&#xD;
&#xD;
          -  Adequate renal function:&#xD;
&#xD;
               -  Creatine clearance ≥ 60 mL/min.1.73m² according to the Schwartz formula [1] or&#xD;
                  its modified form [2]&#xD;
&#xD;
          -  Adequate hepatic function:&#xD;
&#xD;
               -  bilirubin ≤1.5 x ULN&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 x ULN (AST, ALT 5xULN in case of liver metastases)&#xD;
&#xD;
          -  Lansky Score ≥ 70%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are co-administrated at day one with sodium valproate as it decreases the&#xD;
             clearance of temozolomide&#xD;
&#xD;
          -  Patients with (naso)gastric tube administration of temozolomide during first cycle of&#xD;
             treatment.&#xD;
&#xD;
          -  Patients already enrolled in studies investigating temozolomide or other&#xD;
             investigational new drugs.&#xD;
&#xD;
          -  A post-menarche female with a positive blood/urine pregnancy test at inclusion.&#xD;
&#xD;
          -  Known contraindication or hypersensitivity to temozolomide or any chemically close&#xD;
             substance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Abbou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Lemarchand, PharmD</last_name>
    <phone>+33142770818</phone>
    <email>caroline.lemarchand@orphelia-pharma.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hugues Bienaymé, PhD</last_name>
    <phone>+33142770818</phone>
    <email>hugues.bienayme@orphelia-pharma.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Sophie Defachelles, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut d'Hématologie et d'Oncologie Pédiatrique</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Leblond, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Timone Enfants</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas André, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Aerts, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Abbou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité University Medicine Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Thorwarth, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopp Children's Cancer Center Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olaf Witt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Maxima Center for Pediatric Oncology</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natasha Van Eijkelenburg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucas Moreno, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juliet Gray, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuroblastoma</keyword>
  <keyword>other pediatric cancers requiring temozolomide</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

